Langue

Certains contenus peuvent être disponibles uniquement en anglais.

Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Evidence, Guidelines and Recommendations

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Détails

Catégorie
Evidence, Guidelines and Recommendations
Format
Document PDF
Taille du fichier
Fichier introuvable.
Téléchargements
22
Ajouté
25 août 2025
Tags
Psychiatrie
Douleur
Santé mentale
Troubles liés à l'usage de substances
Soins primaires
Médecine interne
Médecine d’urgence

Ressources connexes

Canadian Guideline for Opioids for Chronic Non-Cancer Pain
The Canadian Guideline for Opioid for Chronic Non-Cancer Pain was developed in response to concerns that Canadians are the second highest users per capita of opioids in the world, while the rates of opioid prescribing and opioid-related hospital visits and deaths have been increasing rapidly.